Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications. The company was founded in 2009 and is based in Chengdu, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Yuan, Mingxu

Employees

1,522

Website

www.eastonpharma.cn

IPO Date

2020-09-02

Headquarters

No. 8, Ankang Road, Tianfu International Bio-town, Shuangliu District, Chengdu, Sichuan Province, 610200, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Chengdu Easton Biopharmaceuticals 688513

Chengdu Easton Biopharmaceuticals Earnings Call Summary

Chengdu Easton Biopharmaceuticals Earnings

Transcripts

Events

About Chengdu Easton Biopharmaceuticals Co., Ltd.

Chengdu Easton Biopharmaceuticals
688513